TC
PFE icon

Trilogy Capital’s Pfizer PFE Stock Holding History

Trilogy Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,363
Closed -$241K – 327
2023
Q4 		$241K Sell
8,363
-539
-6% -$16.3K 0.01% 234
2023
Q3 		$295K Sell
8,902
-1,216
-12% -$43K 0.02% 195
2023
Q2 		$378K Buy
10,118
+1,805
+22% +$70.3K 0.02% 194
2023
Q1 		$339K Buy
8,313
+1,806
+28% +$78K 0.02% 190
2022
Q4 		$333K Buy
6,507
+1,606
+33% +$77K 0.02% 186
2022
Q3 		$214K Buy
4,901
+736
+18% +$35.8K 0.02% 169
2022
Q2 		$218K Buy
+4,165
New +$212K 0.02% 150
2019
Q1 		– Sell
-17,235
Closed -$714K – 155
2018
Q4 		$714K Sell
17,235
-1,195
-6% -$49.6K 0.1% 72
2018
Q3 		$771K Sell
18,430
-1,928
-9% -$74.2K 0.1% 72
2018
Q2 		$701K Sell
20,358
-33
-0.2% -$1.13K 0.09% 63
2018
Q1 		$687K Buy
+20,391
New +$701K 0.1% 59

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Trilogy Capital's PFE Position: Q1 2024 in Review

Trilogy Capital sold out of Pfizer (PFE) in Q1 2024, closing a stake of 8,363 shares — an estimated $241K sold.

Trilogy Capital first reported a position in PFE in Q1 2018 and held it in 11 quarters. The position peaked at $771K in Q3 2018. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Trilogy Capital reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Trilogy Capital sold 8,363 Pfizer shares in Q1 2024, an estimated $241K.
  • Trilogy Capital first reported a position in Pfizer in Q1 2018 and held it in 11 quarters.
  • Trilogy Capital's Pfizer position peaked at $771K in Q3 2018.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Trilogy Capital's 13F filing for Q1 2024, filed 17 Apr 2024.